Filing Flows › Aquestive Therapeutics (AQST) › Q2 2026
Aquestive Therapeutics (AQST) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 11, 2026
Aquestive Therapeutics (AQST) reported revenue of $13.8M for the second quarter 2026 (Q2 2026), +38% from a year earlier and -4% from the quarter before. Operating margin was -59.5%, net loss $22.9M (165.5% of revenue).
Aquestive Therapeutics, Q2 2026: revenue $13.8M (+38% year over year), operating margin -59.5%, net loss $22.9M, operating cash flow −$9.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.8M | -4% | +38% |
| Operating profit | −$8.2M | — | — |
| Net earnings | −$22.9M | — | — |
| Operating cash flow | −$9.4M | — | — |
What changed
Revenue was $13.8M in Q2 2026, up 38% year over year and down 4% from the previous quarter. Manufacture and supply revenue was the largest line at 86% of revenue. Manufacture and supply revenue added $2.3M year over year (up 24%), 61% of the total change.
Operating costs exceeded revenue by $8.2M, an operating margin of -59.5%. Total costs grew 3% against revenue growth of 38%. The fastest-growing cost line was SG&A (+11%). The quarter ended with a net loss of $22.9M, wider than the previous quarter's $8.1M loss. Net interest and other expense of $14.6M was the main reason.
Operating cash flow was −$9.4M. Non-cash charges added back $136K of depreciation and $2.9M of share-based compensation. Working capital and other items added $10.4M. Capital expenditures of $212K exceeded it, leaving free cash flow of −$9.7M.
Questions
What was Aquestive Therapeutics' revenue in the second quarter 2026?
Aquestive Therapeutics (AQST) reported revenue of $13.8M for the second quarter 2026 (Q2 2026), +38% from a year earlier and -4% from the quarter before.
Was Aquestive Therapeutics profitable in the second quarter 2026?
Operating loss was $8.2M (-59.5% of revenue) and net loss $22.9M.